Aims
Systematically reviewing the literature found orthostatic hypotension (OH) to be associated with an increased risk of incident dementia but limited data were available in those at highest risk, the hypertensive oldest-old. Our aim was to analyse the relationship between OH and incident cognitive decline or dementia in this group and to synthesize the evidence base overall.
Method and results
Participants aged > _80 years, with hypertension, were from the Hypertension in the Very Elderly Trial (HYVET) cohort. Orthostatic hypotension was defined as a fall of > _15 mmHg in systolic and or > _7 mmHg in diastolic pressure after 2 min standing from a sitting position. Subclinical orthostatic hypotension with symptoms (SOH) was defined as a fall <OH but with unsteadiness, light-headedness, or faintness in the week before blood pressure measurement. Proportional hazard regression was used to examine the relationship between baseline OH, SOH, and cognitive outcomes. There were 3121 in the analytical sample, 538 with OH. Orthostatic hypotension was associated with increased risk of cognitive decline (906 events), hazard ratio (HR) 1.36 (95% confidence interval 1.14-1.59). For incident dementia (241 events), HR 1.34 (0.98- 1.84 ). When competing risk of cardiovascular events were taken into account results were HR 1.39 ( 1.19-1.62 ) and HR 1.34 (1.05- 1.73 ), respectively. Subclinical orthostatic hypotension was associated with an increased risk of cognitive decline HR 1.56 (1.12-2.17 ) and dementia HR 1.79 (1.00- 3.20) . Combining the results from the HYVET cohort in a meta-analysis with the existing published literature in this area found a 21% (9-35%) increased risk of dementia with OH.
.. Conclusion
Orthostatic hypotension indicates an increased risk of dementia and cognitive decline. SOH may also be considered a risk factor, at least in older hypertensive adults. Questions remain regarding the mechanisms and whether interventions to reduce impact of OH could protect cognition. 
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Introduction
Orthostatic hypotension (OH) is a relatively common autonomic failing and is often associated with functional impairment. 1 It is commonly defined as a fall in systolic blood pressure (BP) of at least 20 mmHg and/or a fall of at least 10 mmHg in diastolic BP within 3 min of standing, older adults are at increased risk of OH due to impaired compensatory mechanisms including decreased baroreceptor (pressure) sensitivity, increased arterial stiffness, and reduced parasympathetic tone. 2, 3 Orthostatic hypotension is likely to be a risk factor for a variety of negative health consequences including cardiovascular events, falls, mortality, and poor cognition. This is particularly relevant in older adults where hypertension is prevalent and where levels of frailty and comorbidity may also be high. [1] [2] [3] In 2014, a systematic review found OH to be associated with an increased risk of cardiovascular events. 4 The evidence for an association between OH and cognitive decline in the same systematic review was equivocal. The review found only two eligible studies; one reported no relationship between OH and cognitive outcomes 5 and one other reported an increased risk of cognitive decline with OH. 6 There remains a lack of high quality evidence, and remaining uncertainty, relating to the association between OH and cognitive decline or dementia.
A link between OH and increased risk of cognitive decline is plausible, either directly via variable cerebral perfusion or via increased cardiovascular risk, clinical or subclinical ischaemic events, or via failing homeostatic mechanisms associated with both OH and cognitive decline. 7 This is also particularly relevant to older adults and those with hypertension in whom cerebral auto-regulatory mechanisms may be less able to adapt. 1 With an ageing population and an increased risk of cardiovascular, and cognitive, outcomes associated with increasing age alongside recent work on the role of OH, [1] [2] [3] [4] 7 it is timely to evaluate OH as a predictor for cognitive decline and dementia. To give an updated and unbiased background overview of the current evidence, we used systematic methods to review the literature relating to OH as a risk factor for incident cognitive decline and dementia (see Supplementary material online, Figure S1 and Text S1 for details). Briefly, 21 longitudinal studies on the relationship between OH and incident cognitive decline or incident dementia were found 5, 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] including populations from Sweden, 22, 23 Italy, 23 the Netherlands, 24 Singapore, 6 the United States, 25 and France 26 (see Supplementary material online, Tables S1
and S2). Study sample mean age ranged from mid 22, 25 to latelife 6, 23, 24, 26, 27 and follow-up from 1 to 28 years. 6, [22] [23] [24] [25] [26] [27] Three studies reported presence of OH was associated with an increased risk of dementia. 21, 24, 26 One study found no relationship between baseline OH and dementia, 22 one found no relationship between OH and cognitive decline. 25 Two found no association between OH and risk of a fall in cognitive screening score. 6, 23 Study quality was adequate although details were often lacking (see Supplementary material online, Table S3 ).
Overall, evidence suggests that a diagnosis of OH may be associated with a subsequent increased risk of dementia. However, there are no data available on those at highest risk of hypertension, OH, and cognitive decline or dementia (the oldest old). Furthermore, few studies have investigated the relationship between the magnitude of the orthostatic fall and the degree of risk (i.e. the potential dose response), or the possible influence of 'sub-clinical' orthostatic fall. A greater understanding of relationship between orthostatic fall and cognitive outcome in older adults is essential to be able to identify those at risk of cognitive decline or dementia and to provide appropriate clinical support.
Our aim was to examine the relationship between orthostatic fall and subsequent cognitive decline or dementia in an older adult hypertensive population using data collected as part of the Hypertension in the Very Elderly Trial and to combine our results with the existing evidence base using meta-analysis.
Methods
HYVET was a double blind placebo controlled trial of an antihypertensive regimen (thiazide-like diuretic, indapamide 1.5 sustained release, with the optional addition of an angiotensin converting enzyme inhibitor, perindopril 2-4 mg) in those aged 80 and over. Participants with hypertension were recruited from over 90 primary and secondary care centres in 13 countries and randomised to receive trial treatment or matching placebo. All required ethical approvals were obtained. Participants were seen during a 2-month placebo run-in phase, at baseline, every 3 months during the first year and every 6 months thereafter. Cognitive function was assessed at baseline and annually thereafter using the Mini-Mental State Exam (MMSE). A reduction in MMSE score to below 24 or by more than three points in 12 months was classified as cognitive decline and triggered a dementia assessment. Dementia was diagnosed in accordance with the Diagnostic Statistical Manual IV (DSMIV). Dementia was classified as present or absent. An independent expert dementia committee blind to trial treatment allocation had access to all data and reviewed and validated all dementia endpoints. Other trial endpoints were reported as they occurred and included death, stroke, myocardial infarction, and incident or worsening heart failure. Validation of trial endpoints was carried out by a trial endpoint committee of international experts blinded to trial treatment allocation and with full access to supporting documentation, for example, death certificates, hospitalization reports etc.
To collect data on self-reported symptom burden HYVET trial participants were also asked to self-complete a symptom questionnaire at baseline and annually thereafter. This questionnaire was based on the Bulpitt and Fletcher questionnaire and included a list of symptoms relevant to hypertension and its treatment. 28 Participants were asked to rate the level to which they had been affected by a symptom over the last week. The symptoms light-headedness, unsteadiness, and faintness were selected as relevant to orthostatic drop. The full details of the HYVET protocol have been published elsewhere. 29, 30 In brief, to enter the HYVET trial participants were required to be aged 80 or over at randomisation, to have no clinical diagnosis of dementia, a mean systolic BP 160-199 mm Hg and a standing systolic BP > _140 mm Hg. The sitting BP was taken twice after sitting for 5 min and the standing BP taken twice after standing for 2 min. At study baseline BP was measured using a mercury sphygmomanometer. As supine BP was unavailable OH was calculated based on a fall of > _15 mmHg systolic BP and or a fall of > _7 mmHg diastolic BP from sitting to standing. 31, 32 A novel category of subclinical orthostatic fall with recent symptoms (SOH) was also created. Subclinical orthostatic hypotension was defined as any fall in systolic BP of <15 mmHg on standing and any fall in diastolic BP of <7 mmHg on standing plus symptoms of light-headedness and or unsteadiness and or faintness reported by the participant as having bothered them 'a lot' or 'extremely' during the preceding week. The SOH category was adapted from the orthostatic intolerance definition used by Elmståhl et al. 21 and intended to examine a potential subclinical population.
Statistical methods
The analytical data set consisted of HYVET trial participants who had at least one repeated assessment of cognitive function (allowing evaluation of cognitive decline), complete baseline BP measurements and, in accordance with the literature 6, 21, 24 were without prior stroke. Orthostatic hypotension was classified as present or absent at baseline. The difference in baseline characteristics between those who were included in the analytical sample and those who were excluded, and between those with and without OH, was assessed using v 2 and Wilcoxon tests, as appropriate. Proportional hazard (Cox) regression was used to assess the relationship between those classified as having OH and subsequent cognitive decline or incident dementia. Time to event was calculated from trial entry (the date of first cognitive and BP measure) to the earliest date of event, date of death, or date of last follow-up. The date of the study visit where cognitive decline was identified was taken as the date of event for cognitive decline. The date that cognitive decline was identified was also used for date of dementia where further testing confirmed dementia diagnosis. This is a pragmatic choice since the time interval between the visit where cognitive decline was identified and the subsequent examination to verify diagnosis of dementia varied and as the onset of dementia is an insidious process. Models were stratified [by age (80-84, > _85), sex, and education] and adjusted for key cardiovascular and cognitive risk factors [baseline sitting systolic and diastolic BP, trial treatment (antihypertensive or placebo), and presence of diabetes].
Proportional hazard assumptions were checked using Grambsch and Therneau tests. 27 Overall model fit was assessed visually by plotting the Nelson-Aalen cumulative hazard function against the Cox-Snell residuals. Analyses carried out using SAS 9.3, Stata and Statsdirect 3.
The incidence of mortality, cardiovascular events (myocardial infarction, stroke, or heart failure), cognitive decline, and/or dementia may be interrelated or may all be considered manifestations of the same cardiovascular disease process. We, therefore, performed two further Cox regression analyses, each using a composite endpoint combining cognitive and cardiovascular events in a time to first event model to give greater statistical power and a more holistic outcome measure. In the first, incident dementia or fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, and stroke) were defined as an event and in the second, incident cognitive decline and fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, and stroke) were defined as an event.
Additional analyses were performed with adjustment for incident OH occurring during study follow-up; and, because BP variability may increase the risk of both OH and cognitive decline, analyses were rerun with additional adjustment for visit to visit variability calculated as the standard deviation of the sitting systolic BP values.
Further analyses in the subset of participants who also had symptom data (i.e. had completed the symptom questionnaire) allowed comparison of those with OH, SOH, and neither. The baseline characteristics of these three groups were compared using v 2 and analysis of variance tests for categorical and continuous variables, as appropriate. Pairwise differences were investigated post hoc using the Tukey-Kramer (equal variances) or W test (unequal variances) for continuous variables and by inspection of the adjusted v 2 residuals for categorical variables.
Proportional hazards (Cox) regression was used to assess the relationship between orthostatic status and subsequent cognitive decline or incident dementia with orthostatic status categorised as a three-level variable [OH, SOH, or neither (reference group)]. There were no missing data for the exposure, outcome, or confounding variables used in the analyses.
Sensitivity analyses
The Cox regression analysis was repeated: (i) in those with baseline MMSE >26 (those scoring above 26 at baseline are considered unlikely to have pre-existing cognitive decline, the selection of this population, therefore allowed us to rerun the analyses with less risk of including undiagnosed dementia cases); (ii) for systolic and diastolic OH separately; (iii) for continuous BP fall and risk of subsequent cognitive decline or incident dementia; (iv) using the traditional and more severe classification of OH (a fall of >20 mmHg systolic and or >10 mmHg diastolic);
Finally, the association between baseline OH and subsequent attrition (mortality or drop out) was examined in the analytical sample and inverse probability weighting used to evaluate potential bias stemming from including only those with data on cognitive decline and without stroke.
Meta-analysis
Where possible the results from the HYVET analyses were combined with the existing evidence base was combined with using meta-analytical techniques.
Results
Study population
There were 3845 participants randomized into the HYVET trial with a mean follow-up of 2.0 years. Of those, 508 were excluded from the analysis, because they had no cognitive follow-up assessment and a further 216 due to prior stroke. The analytical sample therefore included 3121 with data on OH and outcome. The subset of those with symptom data and in whom SOH could be calculated contained 2109 participants (see Supplementary material online, Figure S2 for details).
Orthostatic hypotension
Characteristics of the sample (OH) There were 538 participants with OH and 2583 without. Those with OH had higher sitting systolic BP (P < 0.0001) and lower standing systolic (P < 0.0001) and diastolic pressure (P < 0.0001) as would be expected. There were also older (P = 0.004), They also had a lower mean MMSE score at baseline (P = 0.0003), shorter follow-up (P < 0.0001), and a higher percentage of this group were classified as having incident cognitive decline (P < 0.0001) (see Table 1 for details).
Proportional hazard regression (OH)
The estimates of the hazard ratios from the Cox regression models for the association between baseline OH and risk of cognitive decline [hazard ratio (HR) 1.36 There were 315 incident OH cases occurring during study followup n = 169 (5.6/100 patient years of follow-up) in the placebo and n = 146 (4.5/100 patient years) in the actively treated group. Additional adjustment for incident OH resulted in the relationship between OH and incident dementia reaching statistical significance.
Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE scores >26 (n = 1648) resulted in a similar pattern of results and statistical significance as seen when analysing the whole cohort. The only difference was a loss of statistical significance for one analysis, the relationship between OH alone and cognitive decline.
Subclinical orthostatic fall with recent symptoms (SOH) and orthostatic hypotension (OH)
Characteristics of the sample (SOH, OH) In the subset of those for whom symptom data were available (n = 2109) 105 reported SOH, 381 OH, and 1623 neither. The baseline characteristics of the three groups are summarized in Supplementary material online, Table S4 .
When examining the participants with both cognitive and symptom data, there were 105 with subclinical orthostatic fall and positive symptoms, seven with symptoms but neither subclinical nor clinical orthostatic fall and four with symptoms and clinical fall. There are significant differences in the majority of measures between these groups at baseline (all except sitting systolic BP), but there is no consistent suggestion of a linear trend and the only clinically significant differences were between those without any orthostatic fall and those with OH.
Proportional hazard regression (SOH, OH)
The estimates of HRs from the Cox regression models are shown with the associated 95% confidence intervals (CIs) in Table 3 and Figure 1 . Both SOH and OH were associated with an increased risk of cognitive decline. For SOH, HR 1.56 Cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, and stroke) were defined as an event.
b Incident dementia, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, and stroke) were defined as an event.
. Further sensitivity analyses rerunning fully adjusted models in those with baseline MMSE scores >26 and symptom data (n = 914) resulted in a similar pattern of results but the association between OH and cognitive decline was no longer significant. Cognitive decline, fatal and non-fatal cardiovascular events (heart failure, myocardial infarction, and stroke) were defined as an event.
Orthostatic fall and cognitive decline Additional analyses examining cardiovascular events and mortality alone found SOH to be associated with an increased risk of cardiovascular events HR 2.28 (95% CI 1.25-4.14) and mortality HR 2.97 (95% CI 1.76-5.01).
Further examination of the role of symptoms (from the symptoms questionnaire) revealed that presence of self-reported light-headedness and or unsteadiness and or faintness alone (regardless of orthostatic fall) and experienced over the preceding week were not associated with incident cognitive decline or dementia. Rerunning the analysis without the inclusion of symptom data (i.e. SOH classified based on subclinical orthostatic fall alone) resulted in non-significant relationships between sub-clinical orthostatic fall and cognitive decline HR 1.01 (0.82- 1.24 ) and dementia HR 1.05 (0.70-1.58).
Model fit was adequate in all cases and the proportional hazards assumption was not violated.
Sensitivity analyses Systolic hypotension and diastolic hypotension
The analyses were repeated with OH defined using systolic BP fall, systolic OH (n = 218), or diastolic BP fall, diastolic OH (n = 400) (Supplementary material online, Table S5 ). Diastolic OH was associated with an increased relative risk of; cognitive decline HR 1.47 (1.23-1.75), dementia HR 1.69 (1.22-2.34), cognitive decline and cardiovascular events HR 1.49 (1.26-1.75), and dementia and cardiovascular events HR 1.54 (1.18-2.00). There were no significant associations for systolic OH.
Repeating the analyses selecting only those with systolic OH but without diastolic OH (n = 138) and diastolic OH without systolic OH (n = 320) did not materially change the results.
Orthostatic fall
We investigated the relationship between magnitude of the orthostatic fall at baseline and risk of cognitive decline by repeating the Cox regression analysis with orthostatic fall as a continuous variable and for systolic and diastolic BP separately. On average there was a 26% increased relative risk of cognitive decline per 10 mmHg increase (i.e. greater fall in BP) in orthostatic drop in diastolic BP HR 1.26 (1.09-1.42). For systolic BP the results were HR 1.04 (0.94-1.15) per 10 mmHg increase.
Traditional and more severe classification of OH (a fall of 20 mmHg systolic and or 10 mmHg diastolic) The Cox regression analysis was repeated using the classic, more conservative, definition of OH (see Methods section), and the results presented in Supplementary material online, Table S6 . Orthostatic hypotension was associated with an estimated 49% increased relative risk of developing cognitive decline HR 1.49 (95% CI 1.16-1.90 ). This did not change markedly when cognitive decline and cardiovascular events were combined.
Attrition and inverse probability weighting There was no association between OH and subsequent drop out or death (events = 650) odds ratio (OR) 0.86 (95% CI 0.67-1.10). Inverse probability weighting weighted by age, sex, and baseline MMSE score found similarly positive associations between OH and incident cognitive decline (b 0.078, 95% CI 0.045-0.130; P < 0.0001) and dementia (b 0.027, 0.003-0.052; P = 0.034). This implies that the exclusion of those with prior stroke and without follow-up cognitive assessment did not bias the sample in such way as to materially affect the results.
Meta-analysis combining the results from the systematic review and HYVET study 21, 22, 24, 26 The meta-analysis suggested that increased relative risk of dementia was associated with presence of OH. The pooled ratio was 1.21 (1.09- 1.35 ) for fixed effects analysis, see Supplementary material online, Analyses 1 for details of the meta-analysis and forest plot showing the five included studies. The I 2 value for the meta-analysis was 10 .4%, and there was no significant risk of publication bias (Egger bias P = 0.1463). There were insufficient data available from the previously published studies to allow separate meta-analysis relating to systolic, diastolic, or subclinical OH, see supplementary material online, Tables S1 and S2 for details of the studies included in the meta-analysis (populations, age, sex, follow-up, assessment of OH, assessment of cognitive function, analysis methods, and results for these studies). Supplementary material online, Table S3 further details the assessment of study quality and risk of bias.
Discussion
These analyses present new data and shed new light on the relationship between OH and cognitive impairment and dementia.
Orthostatic hypotension and HYVET
When the relationship between OH and incident cognitive decline and dementia was assessed in an older adult hypertensive population from the HYVET trial, baseline OH (sitting to standing) was associated with a 36% increased risk of cognitive decline HR 1.36 (1.15-1.59 ) and a similar point estimate but non-significant relationship with incident dementia HR 1.34 (0.98-1.84 ). Using composite endpoints (i.e. including cardiovascular events) resulted in significant associations with both cognitive decline and dementia, and did not change the magnitude of the point estimates. Further examination of the relationship between subclinical orthostatic drop and cognitive outcomes revealed SOH to be associated with a 56% increased risk of cognitive decline HR 1.56 (1.12-2.17)) and a 79% increased risk of incident dementia HR 1.79 (1.00- 3.20) . Results were similar for composite cognitivecardiovascular endpoints. When systolic and diastolic OH were examined separately results were significant only for diastolic drop.
The relationships between OH and cognitive outcomes in the HYVET trial are not entirely congruent with the literature. In the HYVET data the relationship between OH and cognitive decline was stronger than the equivalent relationship with dementia although both were of similar magnitude, however, there were fewer dementia cases than cases of cognitive decline and thus less power to detect a relationship. The strength of the relationship with SOH and
cognitive decline was also greater than the relationship between SOH and incident dementia, however, both were statistically significant despite the restricted numbers available for these analyses. Neither presence of symptoms alone, nor subclinical orthostatic fall without symptoms were associated with an increased risk of cognitive decline or dementia, therefore the presence of symptoms alongside orthostatic drop may be of particular importance in identifying those at risk of cognitive decline or dementia. Unfortunately, there were too few cases of OH and presence of symptoms to allow evaluation of this category.
The stronger relationship between diastolic when compared with systolic OH and cognitive outcomes in the HYVET trial must be interpreted with caution. Although it is similar to that reported for the Swedish Malmo study and may represent a particular risk associated with a more pulsatile flow and decrease of perfusion in diastole, another explanation relevant to the HYVET data is that the trial inclusion criteria are based on systolic rather than diastolic pressures meaning that the systolic pressures were more homogeneous and clustered just above the required cut-point for trial entry. To enter the HYVET trial participants were required to have a mean systolic BP 160-199 mmHg and a standing systolic BP > _140 mmHg. This resulted in a study population without severe OH and, since there were fewer entrants with very high systolic BP, a mean baseline systolic BP close to the entry threshold. Diastolic pressures did not suffer from the same limitation.
Further limitations include the potential for unmeasured confounding and use of a clinical trial population with randomly allocated antihypertensive treatment and placebo arms. Although we found no relationship between trial treatment group and cognitive outcomes 33 and the analyses were adjusted for trial treatment group it remains possible that there may have been an undetected impact of trial treatment on the relationship between orthostatic drop and cognitive outcomes. The relatively short follow-up and the potential for interaction between BP and cognitive function over a decades long prodromal period prior to the identification of decline is an additional limitation. We have a lack of understanding relating to the long-term relationship between BP and cognition over the life-course and a lack of data prior to participant entry into the HYVET trial at 80 years of age which inevitably restricts our ability to evaluate causality. There is also a challenge in disentangling the potential relationship between early cognitive decline, impaired medication adherence and subsequent change in BP control and OH. Despite this, the results from the HYVET population are in line with those of longer population studies. 21, 22, 24, 26 It may be that OH had been present and incrementally increasing risk either directly or indirectly for many years prior to study start, however, we have no data on OH prior to entry into the HYVET trial. Alternatively the association of OH and cognitive outcomes in this very elderly population may represent failing homeostatic mechanisms and increased BP variability associated with both OH and cognitive decline. Additional adjustment for visit to visit variability had no impact on the results, however, a lack of sufficient data relating to 24 h BP variability (112 HYVET participants had ambulatory BP measurement at baseline) prevented further examination of this area. In fact, since studies with both long and short term follow-up demonstrate a relationship between OH and increased risk, the exact causal pathways, whilst still needing to be established, 34 do not change the overall categorization of OH as an easily measurable factor signalling increased risk.
Orthostatic hypotension and metaanalysis combining the published literature and the HYVET results
The meta-analysis combining HYVET with the published literature found OH to be associated with a 21% increased risk of dementia. Inevitable limitations include variation in length of follow-up, confounders, population characteristics and in the definition and assessment of OH and cognitive outcome plus risk of bias present in the constituent studies. This means that generalizability is limited and, as is common in meta-analyses, caution must be applied.
Summary
The literature overall, including HYVET, is remarkably similar in showing a relationship between OH and risk of dementia. In addition a possible dose response may mean that even subclinical orthostatic fall is associated with raised risk especially in the presence of symptoms associated with OH. However, our analyses cannot establish causality and further research is needed to more fully understand the nature of the relationship between orthostatic drop, speed of recovery, potential difference between systolic and diastolic drop, role of symptoms, related measures such as BP variability, arterial stiffness, impact of early cognitive change on medication availability, or adherence and causal pathways. 34, 35 Causality in this area is complex and although we know from the Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning trial that stopping antihypertensives, at least in those with mild cognitive deficit, increased probability of recovery from OH, this association was not present in the intention to treat analysis and had no impact on cognitive measures. 36 Furthermore, there was no relationship between antihypertensive use and OH in HYVET and antihypertensive use reduced risk of cardiovascular events and mortality 30 meaning we cannot simply recommend the cessation or reduction of antihypertensives. A key question therefore is whether other interventions to minimise the impact of OH [34] [35] [36] [37] have any impact of cognitive outcomes.
Conclusion
Orthostatic hypotension appears to be associated with an increased risk of dementia and of cognitive decline and may be a clinically useful indicator of increased risk. Attention should also be paid to those with subclinical orthostatic drops alongside symptoms indicative of variable cerebral perfusion.
Supplementary material
Supplementary material is available at European Heart Journal online.
